相关实验视频

Updated: Jun 20, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

[关于免疫疗法在非小细胞肺癌中的有效性预测生物标志物的研究进展]

Tiansheng Sun¹, Zhang Chen¹, Kunchen Wei¹

¹Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China.

Zhongguo fei ai za zhi = Chinese journal of lung cancer

|July 19, 2024

概括

确定可靠的生物标志物对于预测非小细胞肺癌 (NSCLC) 患者对免疫检查点抑制剂 (ICI) 的反应至关重要. 本综述探讨了生物标志物,以指导精密免疫疗法,以改善患者的治疗结果.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
基因组学就是基因组学.

背景情况:

非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
免疫检查点抑制剂 (ICI) 已经彻底改变了NSCLC的治疗方法,但反应率有很大的不同.
需要预测性生物标志物来优化ICI治疗选择和患者的治疗结果.

研究的目的:

审查和综合目前关于NSCLC免疫疗法疗效预测生物标志物的知识.
为NSCLC精密免疫疗法的临床应用提供指导.

主要方法:

对NSCLC中ICI治疗的生物标志物研究的综合文献综述.
分析与瘤免疫微环境相关的分子生物学和基因组测序数据.
专注于与患者反应和预后相关的生物标志物.

主要成果:

新兴的生物标志物在预测对ICI治疗的反应方面表现有前途.
了解瘤免疫微环境是生物标志物发现的关键.
目前没有单一的生物标志物可以保证治疗成功的预测.

结论:

可靠的预测生物标志物对于NSCLC个性化免疫疗法至关重要.
对新型生物标志物的持续研究将提高治疗选择和患者的益处.
精密免疫疗法具有显著的潜力,可以改善NSCLC患者的预后.

关键词:

生物标志物生物标志物免疫治疗是一种免疫疗法.肺部瘤是什么肺部瘤预测预测预测预测瘤的突变负担

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...